PROCEPT BioRobotics Management
Management criteria checks 3/4
PROCEPT BioRobotics' CEO is Reza Zadno, appointed in Feb 2020, has a tenure of 4.75 years. total yearly compensation is $6.09M, comprised of 10.1% salary and 89.9% bonuses, including company stock and options. directly owns 0.21% of the company’s shares, worth $10.71M. The average tenure of the management team and the board of directors is 4.8 years and 3.4 years respectively.
Key information
Reza Zadno
Chief executive officer
US$6.1m
Total compensation
| CEO salary percentage | 10.1% |
| CEO tenure | 4.8yrs |
| CEO ownership | 0.2% |
| Management average tenure | 4.8yrs |
| Board average tenure | 3.4yrs |
Recent management updates
Recent updates
Earnings Update: Here's Why Analysts Just Lifted Their PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Price Target To US$102
Oct 31
Procept BioRobotics: New Hydros Aquablation System To Fuel Next Leg Of Growth
Sep 12Procept BioRobotics: Risk Capital Unlock With FDA Hydros Approval
Aug 27Investors Appear Satisfied With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Prospects As Shares Rocket 28%
Aug 25Here's What Analysts Are Forecasting For PROCEPT BioRobotics Corporation (NASDAQ:PRCT) After Its Second-Quarter Results
Aug 04PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S Is Still On The Mark Following 37% Share Price Bounce
May 21The Price Is Right For PROCEPT BioRobotics Corporation (NASDAQ:PRCT)
Apr 05US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results
Mar 01Despite Lacking Profits PROCEPT BioRobotics (NASDAQ:PRCT) Seems To Be On Top Of Its Debt
Feb 07Market Participants Recognise PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Revenues Pushing Shares 26% Higher
Dec 14Is There An Opportunity With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) 43% Undervaluation?
Feb 27Procept Biorobotics announces $52M debt refinancing
Oct 10Providence announces national contract for PROCEPT Biorobotics Aquabeam Systems
Sep 19Procept BioRobotics Has Resources To Ramp Up Commercialization
Sep 01Procept: Leveraging A Novel Water-Based System For Enlarged Prostate Treatment
May 26Need To Know: Analysts Are Much More Bullish On PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Revenues
May 10CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$100m |
| Jun 30 2024 | n/a | n/a | -US$104m |
| Mar 31 2024 | n/a | n/a | -US$103m |
| Dec 31 2023 | US$6m | US$613k | -US$106m |
| Sep 30 2023 | n/a | n/a | -US$107m |
| Jun 30 2023 | n/a | n/a | -US$105m |
| Mar 31 2023 | n/a | n/a | -US$98m |
| Dec 31 2022 | US$4m | US$575k | -US$87m |
| Sep 30 2022 | n/a | n/a | -US$77m |
| Jun 30 2022 | n/a | n/a | -US$69m |
| Mar 31 2022 | n/a | n/a | -US$64m |
| Dec 31 2021 | US$1m | US$490k | -US$60m |
| Sep 30 2021 | n/a | n/a | -US$57m |
| Jun 30 2021 | n/a | n/a | -US$55m |
| Mar 31 2021 | n/a | n/a | -US$53m |
| Dec 31 2020 | US$4m | US$435k | -US$53m |
Compensation vs Market: Reza's total compensation ($USD6.09M) is about average for companies of similar size in the US market ($USD7.78M).
Compensation vs Earnings: Reza's compensation has increased whilst the company is unprofitable.
CEO
Reza Zadno (69 yo)
4.8yrs
Tenure
US$6,088,813
Compensation
Dr. Reza Zadno, Ph D., has been the President, Chief Executive Officer and Director at Procept Biorobotics Corporation since February 2020. Dr. Zadno served as the Chief Executive Officer at Avedro, Inc. f...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.8yrs | US$6.09m | 0.21% $ 10.7m | |
| Executive VP & CFO | 6.1yrs | US$2.67m | 0.11% $ 5.5m | |
| EVP, Chief Legal Officer & Corporate Secretary | 6.3yrs | US$2.19m | 0.031% $ 1.6m | |
| Executive VP & Chief Commercial Officer | 5.7yrs | US$2.63m | 0.014% $ 722.2k | |
| Senior Vice President of Operations | no data | no data | no data | |
| Executive VP of Technology & Clinical Development | less than a year | no data | no data | |
| Vice President of Investor Relations | no data | no data | no data | |
| Chief People Officer | less than a year | no data | no data | |
| Senior Vice President of Regulatory Affairs & Quality Assurance | 2.8yrs | no data | no data |
4.8yrs
Average Tenure
48yo
Average Age
Experienced Management: PRCT's management team is considered experienced (4.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.8yrs | US$6.09m | 0.21% $ 10.7m | |
| Chairperson of the Board | less than a year | no data | no data | |
| Independent Director | 13.3yrs | US$277.64k | 1.49% $ 75.7m | |
| Independent Director | 3.9yrs | US$254.92k | 0.24% $ 12.3m | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 3.1yrs | US$242.16k | 0.015% $ 749.0k | |
| Independent Director | 2.9yrs | US$244.92k | 0.017% $ 863.0k | |
| Independent Director | 9.4yrs | US$247.42k | 0.31% $ 15.9m | |
| Independent Director | 3.4yrs | US$252.42k | 0.0087% $ 441.1k |
3.4yrs
Average Tenure
62yo
Average Age
Experienced Board: PRCT's board of directors are considered experienced (3.4 years average tenure).